Home / Industry News / 2010 / Novartis Should Pay $285 Million in Gender Lawsuit, Bias Lawyer Says

Novartis Should Pay $285 Million in Gender Lawsuit, Bias Lawyer Says

Source: PharmaManufacturing.com

May 19, 2010

Bloomberg.com

Show More Content

More News:

Novartis denies wrongdoing but sets aside $700M for kickbacks lawsuit

07/19/2019

Novartis CEO Vas Narasimhan announced that $700 million has been set aside in the hope of settling a decade-old lawsuit alleging that the Swiss drugmaker bribed U.S. doctors.
Amgen, Allergan launch first anti-cancer biosims in U.S.

07/19/2019

Amgen and Allergan have announced the launch of Mvasi, a bevacizumab biosimilar referencing Avastin, and Kanjinti, a trastuzumab biosimilar referencing Herceptin, in the United States.
Pharma in review: trending stories 7/19/19

07/19/2019

Most popular Pharma Manufacturing stories from the past seven days.
FDA accuses Indian company of shredding documents before inspection

07/17/2019

With the FDA getting ready to knock on their door, officials at Strides Pharma Science Ltd. appear to have attempted to destroy quality-control documents.
Merck’s new antibiotic gets FDA nod

07/17/2019

The FDA has given the go-ahead to an antibiotic developed by Merck to treat urinary tract and abdominal infections.
Novartis sickle cell med nabs accelerated FDA review

07/16/2019

The company's crizanlizumab will receive a priority review, shortening the standard FDA process from ten months to six months.
Gilead to build viral vector facility to strengthen cell therapy capabilities

07/16/2019

The company's Kite Pharma subsidiary will now produce its own Yescarta viral vector material, which it had previosly been purchasing from contractors
Report: J&J facing criminal investigation in ongoing talc scandal

07/15/2019

The Department of Justice is reportedly investigating claims that Johnson and Johnson officials lied about cancer risks tied to its popular baby powder.
Gilead inks $5B deal with Galapagos to bolster pipeline of anti-inflammatories

07/15/2019

Gilead Sciences has struck a major expansion deal with a European biotech firm to target the high-growth anti-inflammatories market.
Boehringer buys cancer vaccines biotech

07/15/2019

Boehringer Ingelheim announced its acquisition of AMAL Therapeutics, a private Swiss biotechnology company focused on cancer immunotherapy.

All news

Pharma Manufacturing

Novartis Should Pay $285 Million in Gender Lawsuit, Bias Lawyer Says

FDA accuses Indian company of shredding documents before inspection

With the FDA getting ready to knock on their door, officials at Strides…

Report: J&J facing criminal investigation in ongoing talc scandal

The Department of Justice is reportedly investigating claims that Johnson…

FDA hands Eton Pharma CRL for eye drops

Eton Pharmaceuticals announced that the U.S FDA provided Eton’s partner…

Product Focus: Advancing aseptic processing

How the pharma industry's big ideas are impacting sterile manufacturing

Gilead inks $5B deal with Galapagos to bolster pipeline of anti-inflammatories

Gilead Sciences has struck a major expansion deal with a European biotech…

FDA pulls 31 ANDAs from troubled generics maker

The challenges are mounting for Canadian generics drugmaker Apotex.

Sun Pharma hit with Form 483 for Halol facility

Sun Pharmaceutical said it has received four observations from the U.S.

Akorn hit with yet another FDA warning letter

The warning letter is the result of an inspection of the company’s…

The top 5 new drugs bound for blockbuster status

A wave of incoming anti-inflammatories and gene therapies that could make…

GSK opens continuous manufacturing plants

GlaxoSmithKline has opened two “state-of-the-art” facilities in…

Merck to cut jobs, close plants with $1.2B restructuring plan

Merck and Co. has created a restructuring plan it says is designed to…

The Highest — and Lowest — Ranked Places to Work in Big Pharma

How pharma companies fair on Glassdoor.

Torrent hit with Form 483

The FDA found that in hundreds of cases, batches at Torrent’s plant did…

Anti-vaxxers turn to potatoes

A new and weird rumor has surfaced in the anti-vaccine movement: potatoes…

Supreme Court sides with Merck in landmark decision

The U.S. Supreme Court gave Merck & Co. a major victory in a case that…